Caricamento...
SAT-621 An Atypical Case of Nivolumab-Induced Thyroiditis with Persistently Elevated Thyroid-Stimulating Immunoglobulin
BACKGROUND: The anti-PD1 monoclonal antibody nivolumab, approved for treatment of several cancers, is associated with ~ 3% rate of hyperthyroidism. Most cases are due to destructive thyroiditis. Stimulating antibodies against the TSH receptor (TSH-R) have not been reported in nivolumab-associated th...
Salvato in:
| Pubblicato in: | J Endocr Soc |
|---|---|
| Autore principale: | |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Endocrine Society
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6552309/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-621 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|